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AbstrAct
Herein, we evaluated the anti-cancer effect and molecular mechanisms of a 
novel betulinic acid (BA) derivative, SYK023, by using two mouse models of lung 
cancer driven by KrasG12D or EGFRL858R. We found that SYK023 inhibits lung tumor 
proliferation, without side effects in vivo or cytotoxicity in primary lung cells in 
vitro. SYK023 triggered endoplasmic reticulum (ER) stress. Blockage of ER stress in 
SYK023-treated cells inhibited SYK023-induced apoptosis. In addition, we found that 
the expression of cell cycle-related genes, including cyclin A2, B1, D3, CDC25a, and 
CDC25b decreased but, while those of p15INK4b, p16INK4a, and p21CIP1 increased following 
SYK023 treatment. Finally, low doses of SYK023 significantly decreased lung cancer 
metastasis in vitro and in vivo. Expression of several genes related to cell migration, 
including synaptopodin, were downregulated by SYK023, thereby impairing F-actin 
polymerization and metastasis. Therefore, SYK023 may be a potentially therapeutic 
treatment for metastatic lung cancer.
IntroductIon
Betulinic acid (BA), a natural pentacyclic triterpene, 
has a variety of beneficial biological activities, including 
anti-tumor, anti-viral, anti-bacterial, anti-malarial and 
anti-inflammatory activity [1, 2]. BA can suppress 
tumorigenesis in several types of cancer, including lung, 
colon, breast, pancreatic, and prostate cancers [3-7]. 
It has been shown to inhibit tumor growth by inducing 
mitochondria-dependent apoptosis [1]. However, BA 
also inhibits the expression of tumor-promoting proteins, 
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including lamin B1, ErbB2, Stat3, HIF-1α and Sp1 
[5, 6, 8]. Further, we have shown that BA inhibits lung 
tumor growth through the inhibition of Sp1-mediated 
cyclin A2 expression in vitro and in vivo [4]. Given the 
effectiveness of BA in inhibiting tumorigenesis, there 
is interest in developing novel derivatives to enhance 
its benefits, while minimizing side effects. Previous 
work has shown that a cyano derivative of BA potently 
inhibits colon and pancreatic cancer. [9]. N-Acylimidazole 
and C-3 carbamate derivatives also enhance the anti-
proliferative effect of BA in HepG2 cells [10]. Moreover, 
2,4-dinitrophenylhydrazone BA derivatives enhance 
cytotoxicity in melanoma, anaplastic thyroid tumors, 
and ovarian, lung, and breast cancer cell lines [11]. 
3-O-Propargylated BA containing 1,2,3-triazoles displays 
a strong anti-tumor effect in leukemia cell lines [12]. In 
addition, ionic and glycosylated BA derivatives display 
increased solubility and improve the anti-tumor effect of 
BA [13, 14]. Our previous study also indicated that 20 mg/
kg of BA can inhibit lung tumor growth in the KrasG12D-
induce lung cancer mice. However, this dose is higher 
than other clinical or pre-clinical used drug. In addition, 
our preliminary results also show that highly frequency 
of lethality occurred after BA injection, suggesting that 
BA cause high cytotoxicity toward normal cell leadings 
side-effect. Based on these studies, to screen the BA 
derivative(s) with higher anti-tumor activity and low side-
effect is crucial for lung cancer therapy. Therefore, we 
tried to develop a new derivative of BA to enhance its’ 
tumor-suppressive effect without increasing the side effect 
in vitro and in vivo.
Previously, BA potently induced protein 
ubiquitination, including Sp1, to decrease proliferation 
followed by apoptosis [4, 15], suggesting that BA 
possibly increases unfolded proteins leading ER stress. 
In this study, to compare the effect between BA and its 
derivatives on tumor suppression, apoptosis triggered 
by various pathways including traditional and ER 
stress-dependent pathways will be addressed. ER stress, 
promotes cell survival by adapting to environmental 
stressors, including the induction of the unfolded 
protein response, aberrant calcium homeostasis, glucose 
deprivation, and viral infection [16]. Under persistent 
stress, the phosphorylation of eukaryotic initiation factor 
(eIF) 2α phosphorylation is induced, thereby inducing C/
EBP homologous protein (CHOP) expression, leading to 
apoptosis [17]. During tumorigenesis, dysregulation of 
the unfolded protein response, such as increased protein 
folding capacity in the ER, can promote cells growth [18]. 
Several drugs including versipelostatin, bortezomib, and 
brefeldin A have been designed to prevent the increase in 
folding capacity, leading to apoptosis [19].
Even though BA was confirmed as a potent anti-
cancer drug, the effects of BA and its’ derivatives on 
metastasis is rarely studied. Herein, we not only study 
the difference between BA and SYK023 in suppressing 
tumorigenesis, but also metastasis. Metastasis occurs 
when cancer cells dissociate from primary tumor, migrate 
through the connective tissue and capillary walls to the 
circulatory system, and form a tumor at a secondary site 
[20]. Numerous processes are involved in the alterations 
to cell shape and migration that promote metastasis, 
including enhanced integrin expression, protease secretion, 
modification of integrin/actin linkage proteins, and the 
coordinated activation of the actin cytoskeleton [20, 21]. 
Many actin-associated proteins such as tropomyosin 
and α-actinin are involved in cancer metastasis [22, 23]. 
Synaptopodin (SYPD), an actin-binding protein, was 
initially identified as a regulator of the dendritic spine 
in telencephalic neurons and the foot processes of renal 
podocytes [24]. Recently, SYPD was shown to regulate 
synapse plasticity [25]. Furthermore, SYPD also stabilizes 
actin microfilaments and Rho family proteins, thereby 
promoting migration [26, 27]. However, the role of SYPD 
in cancer remains unclear despite its ability to regulate 
migration and actin remodeling.
In this study, we used two mouse models with either 
KrasG12D- or EGFRL858R-induced lung tumor to evaluate 
the therapeutic efficacy of BA derivatives. SYK023, a 
derivative of BA, contains stronger inhibitory activity than 
BA in both lung cancer formations through induction of 
ER stress-dependent apoptosis and reduced the metastasis 
of lung cancer by impairing F-actin remodeling. 
results
bA derivatives display enhanced selectivity and 
cytotoxicity than bA on lung cancer in vitro and 
in vivo
Our recent study showed that BA inhibits lung 
tumor growth in vitro and in vivo [4]. To identify the 
compounds that best suppress tumorigenesis, twenty BA 
derivatives were synthesized and their cytotoxicity in 
lung cancer cells was evaluated (Supplementary Figure 
S1). We found that SYK019 and SYK023 (Figure 1A-
1C) inhibited tumorigenesis better than BA. Interestingly, 
neither BA nor SYK023 affected cell survival in normal 
mouse primary lung cells (Figure 1B, left panel and 
Supplementary Figure S2). 
To evaluate the anti-tumor effect of the BA 
derivatives in vivo, we used xenograft models and 
transgenic mice that develop spontaneous lung tumors 
following doxycycline treatment in Scgb1a1-rtTA/TetO-
Kras4bG12D and Scgb1a1-rtTA /TetO-EGFRL858R mice. In 
xenograft models, SYK023 significantly reduced tumor 
volume and weight (Figure 1C and Supplementary Figure 
S3). In physiological evaluation, there is no significant 
difference between normal and lung cancer mice (Table 
1). In particular, we also found that BA and SYK023 
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Figure 1: the improved tumor-suppressive effect of bA derivative, sYK023, on lung cancer, in vitro and in vivo. A. The 
chemical structure of BA, SYK019 and SYK023. b. Effects of BA, SYK019 and SYK023 on cell proliferation of mouse primary cells and 
H1299 cells. Cells were treated with the indicated drug, and trypsinized for counting by hemacytometer. Data are expressed as mean±s.e.m, 
P-value is indicated. To compare the survival curves of BA- and SYK023-treated H1299 cells, two-way ANOVA was used. c. Effects of 
BA and derivatives on tumor growth and physiological functions. After 10 days of tumor xenografting (Day 10), the drug (10 mg/kg) was 
intraperitoneally injected into SCID mice. On Day 25, tumors were exicsed, and serum was collected. d. (a). EGFRL858R mice were treated 
with doxycycline for the indicated period. (b). On the 3rd week, mice were administrated with BA or SYK023 for 9 weeks (10 mg/kg) in 
the presence of doxycycline treatment, and lungs were excised for HE staining.
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did not affect the physiological functions of the liver 
and kidneys by measuring several metabolic enzymes 
(Figure 1C(c)), including glutamic-pyruvate transaminase 
(GPT), glutamic-oxaloacetic transaminase (GOT), alkaline 
phosphatase (ALP), blood urea nitrogen (BUN), and 
creatinine (CRE) (Table 1). 
We next assessed the effect of the BA derivatives in 
the transgenic lung cancer models. After confirming that 
doxycycline-induced lung cancer formation in EGFRL858R 
mice, we treated the mice with BA or SYK023 starting 
at week 3, for 9 weeks total. While BA had a slight anti-
tumorigenic effect, SYK023 potently blocked lung cancer 
progression (Figures 1D, 2A and Supplementary Figure 
S3). Compared to BA, SYK023 also inhibited lung 
tumorigenesis in Kras4bG12D mice, without affecting liver 
and kidney functions (Figure 2B). In contrast, SYK019 
had adverse health effects in mice because the mortality 
of SYK019-injected mice was higher than that of other 
drug-treated mice (Supplementary Table S1). In addition, 
SYK019 was not effective against lung tumors when 
compared to SYK023 (Figure 1C(a-b)). Therefore, we 
did not continue to study the effect of SYK019 on lung 
cancer. Histological analysis of KrasG12D and EGFRL858R 
mice showed that the extent of tumor formation decreased 
in SYK023- treated mice compared to that in BA-treated 
mice (Figure 2A, HE staining). 
We next assessed how SYK023 inhibited lung 
tumor growth. As shown in Figure 2A and 2C, SYK023 
activated the apoptotic pathway, as indicated by the 
increase in active caspase 3, caspase 8 and caspase 
9. Furthermore, SYK023 also induced ER stress, as 
indicated by the phosphorylation of eIF2α, the increase 
in active caspase 12 and the transcriptional upregulation 
of CHOP. Interestingly, Sp1 was also decreased by BA 
and SYK023 in both lung cancer models. These effects 
were more evident in the SYK023 than in the BA treated 
mice, as BA did not induce apoptosis in the lung tumors 
efficiently, and did not induce ER stress in the EGFRL858R 
mice. Taken together, our data indicate that SYK023 has 
improved tumor-suppressive activity compared to BA due 
to its ability to activate caspases and induce ER stress.
sYK023-induced er stress contributes to lung 
cancer cell apoptosis and cell cycle progression
We next studied the detailed molecular mechanism 
of SYK023-induced apoptosis and ER stress (Figure 3). 
In H1299 cells, 10 µM SYK023, not BA, increased the 
expression of apoptotic markers, annexin V staining and 
the percentage of cells in the sub-G1 phase (Figure 3A 
and Supplementary Figure S4A). Moreover, SYK023 
increased eIF2α phosphorylation, active caspase 12, 
X-box-binding protein 1 (XBP1) splicing, and CHOP 
transcription in H1299 cells and xenograft mice, indicating 
that SYK023 induces apoptosis and ER stress in vitro and 
in vivo (Figure 3B-3D). Furthermore, SYK023 (10 µM), 
not BA, increased total protein ubiquitination (Figure 
3E), suggesting that the accumulated misfolded proteins 
are degraded by the ER-associated degradation pathway 
during the process of ER stress. ER stress was previously 
shown to induce apoptosis through the impairment of 
mitochondrial membrane potential, resulting in the release 
of cytochrome c. SYK023 strongly induced the release of 
cytochrome c from the mitochondria to the cytosol (Figure 
3F), suggesting that SYK023-induced apoptosis is partially 
dependent on ER stress. To explore whether the apoptosis 
was mediated by ER stress, the eIF2α inhibitor, salubrinal 
(SAL), was used. We initially confirmed that SAL is an 
eIF2α dephosphorylation inhibitor in Supplementary 
Figure S4B [28]. In Supplementary Figure S4C, SAL 
did not induce ER stress and apoptosis, characterized by 
active caspase 12 and caspase 3, respectively, in H1299 
cells. Therefore, pretreatment with SAL for 2 h does not 
influence cell survival in subsequent experiments. We 
also further confirmed that SAL significantly prevented 
tunicamycin (TM)-induced ER stress (Supplementary 
Figure S4D). By the way, both the reactive oxygen species 
(ROS) scavenger, N-acetyl-L-cysteine (NAC) [7], and 
SAL partially inhibited BA- and SYK023-induced cell 
table 1: the physiological parameters of mice receiving dMso, bA or sYK023.
Mice Parameters dMso (d) bA sYK023 d vs bA d vs sYK
Kras4bG12D
(n=8)
ALP (U/L) 233±15.2 197±14.8 182±16.1 P=0.1118 P=0.0375*
GOT (U/L) 51.9±7.9 48±2.9 50.9±6.2 P=0.6509 P=0.9217
GPT (U/L) 38.4±6.2 30.6±3.2 38.1±2.8 P=0.2843 P=0.9711
BUN (mg/dl) 25.5±2 29.6±1.6 26.1±1.7 P=0.1279 P=0.8141
CRE (mg/dl) 0.6±0.08 0.5±0.08 0.4±0.09 P=0.6160 P=0.2158
SCID
(n=6)
ALP (U/L) 153.5±24.6 100.3±3.6 116.2±8 P=0.0586 P=0.1803
GOT (U/L) 93.8±18.8 121±16.1 104.8±5 P=0.2977 P=0.5838
GPT (U/L) 28.8±3.7 26.3±4.2 17.7±2.4 P=0.6660 P=0.0303*
BUN (mg/dl) 29.7±1.4 33.7±3.1 36.9±6.2 P=0.2703 P=0.2774
CRE (mg/dl) 0.4±0.04 0.5±0.1 0.6±0.1 P=0.3293 P=0.1284
Data were expressed as mean±s.e.m.
*P<0.05
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Figure 2: sYK023 activates caspase cascade and induces er stress in vivo. A. Effects of BA and SYK023 on lung tumor 
progression in KrasG12D and EGFRL858R transgenic mice. After treatment with BA or SYK023 (10 mg/kg), lungs were excised for histological 
staining. Scale bar means 1 cm. b. The number of tumor nodules on lung surface of KrasG12D mice. The serum was collected for evaluating 
liver and kidney functions. Data are expressed as mean±s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001. c. The whole tissue extracts of 
lungs were prepared for Western blotting. The mRNA was subjected to reverse transcription and Q-PCR. Data are expressed as mean±s.e.m, 
P-value is indicated.
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Figure 3: sYK023 induces er stress-dependent apoptosis in lung cancer. A. After treatment with BA or SYK023, H1299 cells 
were subjected to flow cytometry. b. Cells were harvested for Western blotting. c. Upper, the splicing of XBP-1 was analyzed by PCR 
following agarose electrophoresis. Lower panel, The quantitated result of XBP-1 splicing. Spliced form was normalized with unspliced 
form. d. Whole tissue extracts of tumors from H1299-xenografted SCID mice were analyzed by Western blotting. e. After treatment for 36 
h, H1299 cells were harvested for Western blotting. F. Cytosolic and mitochondrial fractions were prepared for Western blotting. G. After 
pre-treatment with SAL (50 µM) for 2 h, H1299 cells were treated with BA or SYK023 for 36 h. Cell lysates were analyzed by Western 
blotting and qPCR. H. After CHOP knockdown, cells were treated with BA or SYK023 for 36 h. Cell lysates were analyzed by Western 
blotting and qPCR.
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death (Supplementary Figure S4E). In particular, when 
ER stress was inhibited by SAL (Figure 3G) or CHOP 
knockdown (Figure 3H), BA and SYK023 failed to induce 
the intrinsic apoptotic pathway. These results suggest that 
SYK023-induced ER stress increases apoptosis of lung 
cancer cells. 
We next assessed how SYK023-induced ER stress 
affected cell survival at the molecular level. Global gene 
expression profiles of lung cancer cells with or without 
SYK023 treatment were analyzed by cDNA microarray 
(Figure 4A-4B). Interestingly, genes involved in cell 
proliferation were downregulated following SYK023 
treatment. In contrast, genes related to cell cycle arrest 
and apoptosis were upregulated (Figure 4A-4B). In mice 
with lung cancer, both of BA and SYK023 obviously 
decreased the levels of cyclin A2 and cyclin E2, whereas 
those of p15INK4b and p21CIP1 increased (Figure 4C). 
Further, microarray analysis identified that the cyclin 
B1-interacting E3 ligase was upregulated by SYK023 
(data not shown), suggesting that cyclin B1 levels may 
be decreased.. Accordingly, SYK023-treated mice 
exhibited lower expression of cyclin B1; however, BA 
did not affect cyclin B1 expression. This result suggests 
that the downregulation of cyclin B1 may regulate the 
enhanced anti-tumor effect of SYK023 versus BA. 
Furthermore, the downregulation of cyclin A2, cyclin 
B1, CDC25a, CDC25b, CCND3, and CDC6 by SYK023 
and the upregulation of p15INK4b, p16INK4a, p57KIP2, and 
CHOP by SYK023 were reversed by blocking ER stress 
(Figure 4D-4E). However, the upregulation of p21CIP1 and 
the downregulation of proliferating cell nuclear antigen 
(PCNA) were not dependent on ER stress, suggesting that 
SYK023 inhibits cell cycle progression through ER stress-
dependent and -independent pathways. 
sYK023 inhibits lung tumor metastasis through 
the inhibition of F-actin polymerization
Using both transwell invasion and wound-healing 
assays, we found that SYK023 (0.5 µM) obviously 
inhibited migration without causing cell death, as 
compared to BA (5 µM) (Figure 5A and Supplementary 
Figure S5). Furthermore, compared to BA, SYK023 (2 
mg/kg) significantly inhibited metastasis in vivo (Figure 
5B). Because F-actin regulates cytoskeletal dynamics to 
promote migration, we assessed whether BA and SYK023 
affected F-actin remodeling. We found that F-actin 
polymerization was attenuated by SYK023 (0.5 µM) or 
by BA (5 µM) (Figure 5C and Supplementary Figure 
S6). Strikingly, increased doses of SYK023 both blocked 
F-actin polymerization and decreased the F-actin levels. 
These results suggest that SYK023 inhibits migration by 
inhibiting F-actin polymerization.
Based on these data, we investigated the effect 
of SYK023 on signaling pathways that mediate F-actin 
remodeling. The phosphorylation of FAK, Src, Akt and 
mTOR, all of which promote F-actin polymerization 
[29-31], was reduced by SYK023 (Supplementary 
Figure S7A). In addition, we found that SYK023 (5 µM) 
effectively decreased the expression of some proteins that 
promote lung tumor formation (Supplementary Figure 
7B), including N-cadherin, β-catenin, vimentin, and c-myc 
[32-35]. These findings support the notion that low doses 
of SYK023 can impair F-actin and oncoprotein expression, 
without inducing apoptosis. Similar effects were not 
observed with BA. Moreover, microarray analysis, which 
functionally grouped using the Gene Set Enrichment 
Analysis website (Figure 6A), revealed that several genes 
related to migration were decreased by SYK023, including 
Rho family proteins, contactin-1, intermediate filament 
proteins and tubulins [36-39]. These data suggest that 
SYK023 inhibits migration by dysregulating cytoskeletal 
structure.
 Interestingly, the actin-binding protein SYPD was 
also downregulated by SYK023. SYPD, is known to 
regulate cell migration and to stabilize RhoA in podocytes. 
[27]. Importantly, SYPD has never been studied in 
cancer. We confirmed that SYPD knockdown blocked 
F-actin polymerization and expression (Supplementary 
Figure S8). Moreover, SYPD expression was decreased 
by BA (20 µM) and SYK023 (1 µM) (Figure 6B). 
Furthermore, in addition to attenuating migration, SYPD 
knockdown prevented the inhibitory effect of BA and 
SYK023 on migration and F-actin remodeling (Figure 
6B). In conclusion, many proteins including SYPD, are 
involved in F-actin polymerization and are down regulated 
following SYK023 treatment.
overexpression of sYPd is a biomarker of lung 
cancer to predict poor prognosis
Since the role of SYPD in cancer is unknown, we 
assessed whether SYPD is important for lung cancer 
progression. Compared with IMR cells, a normal 
pulmonary fibroblast cell line, the protein level of SYPD 
was increased in lung cancer cells, including CL1-0, CL1-
5 and A549 cells (Figure 6C). In KrasG12D mice (Figure 
6D), SYPD expression was upregulated in lung tumors. 
As expected, SYPD was reduced in the lungs of BA- and 
SYK023-treated KrasG12D mice. To establish the clinical 
relevance, we analyzed the SYPD level in normal and 
tumor tissues from lung cancer patients that underwent 
surgery (Figure 6E and Supplementary Figure S9). In 
59 patients, 43 exhibited higher SYPD expression in 
tumor tissue compared to normal tissue. In addition, the 
mRNA level of SYPD was significantly higher in lung 
tumors. Importantly, we found that SYPD overexpression 
correlated with poor prognosis, suggesting that SYPD, 
an actin-binding protein, participates in lung cancer 
malignancy. 
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Figure 4: Gene expression profile altered by SYK023-induced ER stress. A. Micorarray analysis of DMSO- and SYK023 (20 
µM)-treated cells. b. Cell cycle regulators affected by SYK023 were summarized. Red is upregulation, and green is downregulation. c. 
Upper panel, lysates of lungs were analyzed by Western blotting. Lower panel is quantitated results. d. Upper panel, whole cell lysates of 
H1299 were prepared for Western blotting. Lower panel panel is quantitated results. E. The mRNA was analyzed by Q-PCR using indicated 
primers. Data are expressed as mean±s.e.m. Compared with DMSO without SAL: *P < 0.05, **P < 0.01 and ***P < 0.001. The comparison 
between groups with or without SAL: #P < 0.05, #P < 0.01 and #P < 0.001.
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dIscussIon
In this study, we screened a new BA derivative, 
SYK023, with higher tumor-suppressive activities and 
lower side-effect to normal lung normal cells compared 
to BA and other BA derivatives. Although several other 
BA derivatives have been studied, the in vivo evidence 
of anti-tumor activity is still unclear. Herein we not only 
used more in vivo tool, spontaneously lung cancer animal 
models to evaluate the anti-tumorigenesis activity of 
SYK023, but first time found SYK023 with anti-metastasis 
activity through affecting F-actin polymerization. 
BA has been shown to have anti-virus, anti-
inflammation and anti-cancer activity [1]. BA has been 
shown to inhibit a variety of cancers, including melanoma, 
head and neck, colon, breast, neuroectodermal tumors, 
Figure 5: effects of bA and sYK023 on lung tumor metastasis in vitro and in vivo. A. After BA and SYK023 treatment for 
36 h, H1299 cells were subjected to transwell invasion and wound-healing assay. b. Representative images of lungs from SCID mice with 
metastasis (a). The number of surface lung tumors. Data are expressed as mean±s.e.m, P-value is indicated (b). c. H1299 cells on the 
coverslip were treated with the indicated drug, and subjected to immunoflurescent staining for F-actin and DAPI (1000x).
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Figure 6: sYK023-targeted sYPd is a novel biomarker of lung cancer. A. Micorarray analysis of DMSO- and SYK023-treated 
cells. Q-PCR for SYPD. b. After transfection with scramble or SYPD shRNA for 48 h, cells were trypsinzed for Western blotting (a), or 
seeded onto coverslips for immunofluorescence of F-actin (200x) (b). c. The cell lysates were analyzed by Western blotting. d. Lung 
tissues from KrasG12D mice were analyzed by Western blotting (a and c) and immunohistochemistry for SYPD (b). e. The mRNA level of 
normal and cancer from lung cancer patients was analyzed by Q-PCR. Data are expressed as mean±s.e.m, P-value is indicated (a). The 
representative images of overexpression and normal expression of SYPD protein in human lung cancer (b). The survival rate of 59 lung 
cancer patients according to the level of SYPD (c).
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prostate, renal, ovarian, lung, and cervical cancers, as well 
as leukemia, as assessed in cancer cell lines or xenograft 
mouse models [1, 3-7]. Furthermore, we recently used 
xenograft mouse models and a KrasG12D-induced lung 
cancer mouse model to assess the effect of BA , and 
found that it suppresses tumorigenesis by inhibiting cell 
cycle progression [4]. Collectively, previous studies 
indicate that BA inhibits tumorigenesis by promoting 
mitochondria potential-induced cell apoptosis and the 
inhibition of cellular proliferation [1]. In this study, we 
studied the effect of 27 BA derivatives on lung cancer 
cell proliferation. Several derivatives including SYK010, 
SYK019 and SYK023 were more cytotoxic in lung cancer 
cells than BA (Supplementary Figure S1). Further testing 
revealed that SYK023 had fewer side effects in primary 
lung cells and mice than BA, SYK010 and SYK019 
(Supplementary Table S1). Therefore, we assessed the 
molecular mechanisms by which SYK023 inhibited lung 
tumorigenesis. Previous studies indicated that BA inhibits 
the proliferation of cancer cells through inhibiting cell 
cycle progression and triggering the intrinsic apoptotic 
pathway [1]. In this study, we found that SYK023 not only 
induced cell cycle arrest and extrinsic apoptotic pathway, 
but also induced ER stress-dependent intrinsic apoptosis. 
Microarray analysis revealed that the mRNA level of 
CCNB1 was not altered following SYK023 treatment; 
however, CCNB1 interacting protein 1 (CCNB1IP1), an 
E3 ubiquitin ligase targeting cyclin B1 [40], was increased 
(data not shown), suggesting that SYK023 may affect 
more anti-tumor pathways than BA to inhibit cancer 
cell proliferation. We then hypothesized that SYK023 
may enhance the E3 ligase activity of CCNB1IP1 to 
degrade cyclins. In addition, SYK023 may also induces 
the expression of other unknown E3 ligases, based on 
the strong ubiquitinated signal in SYK023-treated cells 
(Figure 3D). Simultaneously, this signal may be attributed 
to the accumulation of unfolded proteins leading to 
ER stress or the inhibition of multiple deubiquitinases 
in cancer cells [15]. The other nature compound, 
oplopantriol, exhibits activity similar to that of SYK023, 
inducing the accumulation of ubiquitinated proteins and 
ER stress [41]. In the past, several well-known anti-
cancer drugs exert their tumor killing effects through the 
induction of ER stress, including bortezomim, brefeldin A, 
curcumin, celecoxib, and heat shock protein 90 inhibitors 
[42]. 
To confirm whether SAL increases eIF2α 
phosphorylation [28], we treated H1299 cells for the 
indicated period. As shown in Supplementary Figure 
S4B, SAL did not affect p-eIF2α level until 16th h. In our 
experiments which combines SYK023 and SAL, cells 
were pre-treated with SAL for only 2 h. Therefore, SAL-
only should not affect eIF2α phosphorylation when cells 
were treated with BA or SYK023. When we performed 
experiments related to SAL, time of SAL treatment is 
only 2h. We thought this treatment time do not affect cell 
survival. However, to test whether SAL induces ER stress 
or apoptosis, we treated H1299 cells with SAL (50 μM) 
for 24h. As shown in Supplementary Figure S4C, SAL did 
not decrease proliferation until 36h, indicating that SAL 
did not affect cell survival during the period of SYK023 
treatment. Compared with tunicamycin treatment for 
24h, neither caspase 12 nor caspase 3 cleavage was not 
induced by SAL. CHOP transcription was not induced by 
SAL. Based on this data, we make sure that treatment of 
H1299 cells with SAL for 24h did not induce ER stress or 
apoptosis. Because we cannot explain why combination 
of SYK023 with SAL decreases eIF2α phosphorylation. 
We used caspase 12 and CHOP mRNA as the ER stress 
marker instead of p-eIF2α (Figure 3G) [43, 44]. However, 
SAL still attenuated SYK023-induced caspase 12 cleavage 
and CHOP expression (Figure 3G). In microarray results 
(Figure 4A(b)), PPP151A/GADD34, which was shown 
to dephosphorylate eIF2α phosphorylation [45], was 
increased by SYK023. The inhibitory effect of SAL 
on eIF2α phosphorylation maybe thus antagonized by 
SYK023 through GADD34. In Figure 3G, SAL prevented 
SYK023-induced apoptosis, suggesting that SYK023 
causes cell death through inducing ER stress. Moreover, 
SYK023-mediated cytoskeleton impairment also 
contributes to prevent metastasis activity of lung cancer. 
In Figure 5B, 2 mg/kg of SYK023, not BA, significantly 
inhibited metastasis in vivo, suggesting that, in this study, 
we screen a BA derivative, SYK023, contains higher 
inhibited activities of tumorigenesis and metastasis and 
lower side-effect in normal cells. In addition, previous 
studies also indicated that BA decreases Sp1 levels in 
prostate and lung cancers [3, 23]. 
In studying the effects of SYK023 and BA in the 
KrasG12D- and EGFRL858R-induced lung cancer mouse 
models, we found that SYK023 dramatically inhibited 
lung cancer nodule formation in both systems (Figures 
1D, 2A and 2B). However, BA inhibited KrasG12D-induced 
lung cancer formation significantly, but had the slightly 
inhibitory effect on EGFRL858R-induced lung cancer 
(Figures 1D, 2A and 2B). Furthermore, we also found that 
Sp1 was dramatically accumulated in the lung tissue of 
KrasG12D-induced lung cancer mice [46] but not found in 
EGFRL858R-induced lung cancer mice. According to the 
results of this study, we hypothesized that inhibition of 
lung cancer growth by BA is through Sp1 degradation, 
and in contrast, that of SYK023 is through both Sp1 
degradation and ER stress. Our previous study indicated 
that there is an inverse correlation between Sp1 level and 
prognosis in clinical lung cancer patients, suggesting 
that SYK023, but not BA, may be the better therapeutic 
option for lung cancer, particularly for that without Sp1 
accumulation which is associated with poor prognosis 
[46].
The anti-tumor activity of BA in vivo is much poorer 
than that of SYK023, especially in EGFRL858R mice (Figure 
1), suggesting that, compared to SYK023, BA requires 
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much higher dose for tumor therapy in vivo. This increases 
the possibility of side effects. Although BA did not affect 
the survival of normal cells, it still cause the death of 
mice during the period of treatment (Supplementary Table 
S1). Herein, the number of dead mice by SYK023 was 
obviously fewer than that by BA, suggesting that the 
tolerance of mice to SYK023 is much better than that 
to BA. SYK023 highly improved the cytotoxicity of BA 
in tumor cells without increasing the occurrence of side 
effect. This enhances the worth and possibility of the BA 
derivative, SYK023, in clinical usage. Based on results 
of Figures 2 and 5, the working dose of SYK023 and BA 
is 2-5 mg/kg and 10-20 mg/kg, respectively. For a 70 kg 
of man with lung cancer, the pastille form of SYK023 is 
140-350 mg/tab, which is similar with that of gefitinib 
(250 mg/tab) and is easily received by patients; that of BA 
requires 700-1400 mg/tab. In addition, in Figures 2C and 
3D, SYK023, not BA, potently induced extrinsic apoptosis 
which was not dependent on ER stress (Figure 3G).
In this study, we established that BA and SYK023 
can inhibit the metastasis of lung cancer. Low dose 
SYK023 (0.5 µM) significantly inhibited lung cancer 
metastasis (Figure 5). Gene expression profile analysis 
revealed that several metastasis-related genes, including 
SYPD, were decreased following SYK023 treatment 
(Figure 6), suggesting that SYK023 might affect the 
expression of many actin polymerization-related genes to 
inhibit lung cancer cell migration. However, how SYK023 
inhibits gene expression remains unclear. Our analysis also 
revealed that SYK023 decreased the phosphorylation of 
Src, FAK, Akt and mTOR (Supplementary Figure S7), all 
of which are involved in cell survival, apoptotic pathways, 
and actin polymerization in lung cancer [47, 48]. In 
Figure 4D, SAL partially reversed the decrease of cyclin 
expression by SYK023, suggesting that SYK023 reduces 
cyclin through ER stress-dependent and -independent 
pathway. In addition to inducing ER stress, SYK023 (1 
μM) also destroyed cytoskeleton. This is not contributed 
by ER stress. The impairment of cytoskeleton also 
contributes to the alteration of gene profile. Some genes 
dysregulated by SYK023 are through ER stress, some are 
independent of ER stress. BA-induced ER stress maybe 
not enough to drive cells for apoptosis. It is possibly 
reversible. At 20-30 μM, the cytotoxicity of BA maybe 
restricted in ER stress-induced mitochondria dependent 
apoptosis. Therefore, BA-induced the alteration of gene 
expression was prevented by inhibiting ER stress.
Metastasis is the most serious cancer-related 
problem because it is not easily diagnosed in lung cancer 
and often occurs before cancer has been diagnosed. 
Treatments for lung cancer, including radiation, 
chemotherapy, surgery, and targeted therapy, are options 
for treating lung cancer that has metastasized to the liver, 
brain, and bone. Testing can be performed to distinguish 
if the cancer expresses mutations that have a targeted 
therapy. For example, if a patient has an EGFR mutation, 
erlotinib (Tarceva) and gefitinib (Iressa) can be used [49]. 
Alternatively, the presence of an anaplastic lymphoma 
kinase (ALK) gene abnormality allows for treatment 
with crizotinib (Xalkori) [50]. In addition, other specific 
abnormalities, such as RET, ROS-1, and KRAS mutations 
are being studied to develop specific inhibitors. In this 
study, SYK023 was used in KrasG12D- and EGFRL858R-
induced lung cancer to inhibit cancer formation (Figure 
1), suggesting that SYK023 is useful for treating lung 
cancer having oncogene mutation. Furthermore, various 
metastasis-related experiments were performed in vitro 
and in vivo to show that SYK023 not only decreases cancer 
cell proliferation but also inhibits lung cancer metastasis 
at low doses. In addition to SYPD, several cytoskeletal 
proteins known to regulate migration or invasion were 
also decreased by SYK023, including Rho family proteins 
[51, 52], contactin-1 [53], filamin A [54], synemin [38], 
capping protein [55], actin-binding LIM protein 1 [56], 
TRIO, [57] and tubulin family [52] (Figure 6A). Based on 
these findings, SYK023 may be a viable treatment for lung 
cancer metastasis, either alone or in combination, without 
causing damage to normal cells. 
MAterIAls And MetHods
cell culture and chemical compounds
H1299 and A549 lung cancer cell lines were 
purchased from American Type Culture Collection 
(Manassas, VA, USA). The CL-series cell lines were 
provided by Dr. Pan-Chyr Yang (National Taiwan 
University, Taipei, Taiwan). These cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen, Carlsbad, CA, USA) supplemented with 
10% FBS (Invitrogen), 100 mg/ml streptomycin sulfate 
and 100 U/ml penicillin G sodium at 37oC in 5% CO2. 
Normal mouse primary lung cells were isolated from lungs 
homogenized by using 0.5% collagenase (Sigma-Aldrich, 
St. Louis, MO, USA) and 0.05% trypsin (Biological 
Industries, Kibbutz Beit Haemek, Israel) at 37oC for 1 h. 
After centrifuging at 1200x g for 20 min, and filtering, 
cells were resuspended by DMEM-10% FBS, and seeded 
onto 6-well plates. BA was purchased from Sigma-
Aldrich. Compounds SYK001, 002, 003, 004, 005, 006 
and 009 were synthesized according to the previous study 
[58]. The eIF2α inhibitor, salubrinal, was purchased from 
Biovision (Milpitas, CA, USA). BA, the derivatives and 
salubrinal were dissolved in dimethyl sulfoxide (DMSO; 
Sigma-Aldrich). 
transfection
H1299 cells were transfected with indicated shRNA 
with lipofectamine 2000 (Invitrogen) according to the 
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manufacture in Opti-MEM for 9 h, and incubated for 
additional 16 h for subsequent experiments.
the synthesis of other sYK compounds
The synthetic protocol of SYK compounds was 
described in Supplementary Materials and Methods.
General experimental procedures for drug 
synthesis
1H NMR spectra were measured on a 400 MHz 
Varians Gemini 2000 spectrometer using TMS as internal 
standard. NMR spectra were recorded in CDCl3. Mass 
spectra were recorded on a Shimadzu LC-MS2010 
instrument. Analytical TLC was performed on pre-
coated silica gel GF plates from Merck, Inc (Darmstadt, 
Germany). Medium-pressure column chromatography was 
performed using a CombiFlash® Companion system from 
ISCO, Inc (Columbus, Ohio, USA). 1-naphthoic acid and 
4-benzyloxyphenylacetic acid were purchased from Acros 
Organics (Geel, Belgium) and TCI Co., Ltd. (Tokyo, 




A solution of 4-methoxyphenylacetic acid (94.8 mg, 
0.57 mmol) in CH2Cl2 (4.5 mL) and Et3N (0.5 mL) was 
treated with EDCI (86.6 mg, 0.56 mmol) and DMAP (57.6 
mg, 0.47 mmol), and 20 min later betulinic acid (49.4 mg, 
0.11 mmol) was added. The reaction mixture was stirred 
overnight before water was added. The mixture was 
extracted with CH2Cl2, washed with brine, and dried over 
MgSO4. The solvent was removed, and the residue was 
submitted to Medium-pressure column chromatography 
with n-hexane/EtOAc to give SYK023 (11.8 mg, 18%) as 
white powder; 1H NMR (400 MHz, CDCl3): δ 7.29 (2H, 
d, J = 8.8 Hz, Ar-H-2, 6), 6.85 (2H, d, J = 8.8 Hz, Ar-H-3, 
5), 4.73 (1H, d, J = 1.5 Hz, H-29), 4.61 (1H, br s, H-29), 
4.45 (1H, dd, J = 5.8, 10.8 Hz, H-3), 3.79 (3H, s, OCH3), 
3.54 (2H, s, OCOCH2Ph), 3.00 (1H, dt, J = 4.9, 10.8 Hz, 
H-19), 1.69 (3H, s, H-30), 0.96, 0.92, 0.83, 0.77, and 0.74 
(3H each, s, 5 × CH3); MS m/z: 603.45 (M – H)
-. This 
compound, SYK023, was dissolved in 100% DMSO for 
all the experiments here.
Animal experiments
The experiments related with animals were 
approved by the Institutional Animal Care and Use 
Committee at National Cheng Kung University (NCKU). 
Scgb1a1-rtTA/TetO-Kras4bG12D transgenic mice were 
generated as described previously [46]. Both of Scgb1a1-
rtTA and TetO-EGFRL858R mice were purchased from 
Jackson Lab (Bar Harbor, MA, USA). After breeding, 
Scgb1a1-rtTA/TetO-EGFRL858R mice were used to study 
lung cancer. To induce lung cancer progression, two 
month-old of transgenic mice were orally administrated 
with doxycycline dissolved in RO water (0.5 g/liter). 
For drug administration, Scgb1a1-rtTA/TetO-Kras4bG12D 
mice receiving doxycycline for 3 months were injected 
intraperitoneally with BA or its derivatives (once/3 
days) for 2 months in the presence of doxycycline 
administration. Scgb1a1-rtTA/TetO-EGFRL858R mice 
receiving doxycycline for 3 weeks were injected with BA 
or its derivatives (10 mg/kg, once/3 days) for 9 weeks. 
To establish the xenograft model, male athymic 
BALB/c severe combined immunodeficiency (SCID) mice 
(8 week-old) were purchased from the Animal Center of 
NCKU. H1299 cells (1 x 106) in 100 µl PBS were injected 
into the back of mice. After 10 days mice with obvious 
tumor formation were injected intraperitoneally with BA 
or its derivatives (once/3 days) for 15 days. During the 
period of 15 days, tumor size was measured once/2 days 
according to the previous study [4].
For metastasis assay in vivo, on Day 1, CL1-5 cells 
(1 x 106) in 100 µl of PBS were injected into the right 
lateral tail vein of male athymic BALB/c nude mice (8 
week-old). Drugs were injected intraperitoneally into mice 
once/3 days until Day 45. After sacrificing, lungs were 
excised for counting tumor nodules.
Physiological evaluation
After sacrificing, blood of mice were collected 
and centrifuged at 12000 rpm for 30 min at 4oC. The 
supernatant representing serum was analyzed by FUJI 
DRI-CHEM 4000i system (FUJIFILM Corporation, 
Tokyo, Japan) to measure indicated physiological 
parameters. The values of BA- or SYK023-treated group 
were compared with DMSO-treated group (DMSO), 
whose lung tumors spontaneously develop. The values of 
normal mice which did not develop lung tumor with or 
without DMSO injection were also shown in Table 1.
Western blotting
The process was performed according to the 
previous study [46]. After blocking by 5% non-fat milk, 
PVDF membrane (Millipore, Bedford, MA, USA) was 
incubated with the primary antibody which was listed in 
Supplementary Materials and Methods. at 4oC overnight. 
After incubation with the anti-rabbit or anti-mouse IgG 
conjugated with horseradish peroxidase (Millipore) for 
1 h at room temperature, signals were detected using 
chemiluminescence Alpha Innotech detection system 
(Alpha Innotech Corp., San Leandro, CA, USA).
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Preparation of mitochondria and cytosolic 
fractions
The procedure of this experiment was performed 
using Mitochondria Isolation Kit (Thermo Scientific 
Pierce, Rockford, IL, USA) according to the manufacture. 
Briefly, cells were harvested in Reagent A, and mixed with 
Reagent B. After mixing with Reagent C, cell suspension 
was centrifuge at 700 x g for 10 min at 4oC. Subsequently, 
the mitochondria fraction was pelleted by centrifuging 
supernatant at 12000 x g for 15 min at 4oC, and the 
supernatant represented the cytosolic fraction. The pellet 
was washed once by Reagent C, and mixed with sample 
buffer for Western blotting analysis.
Immunohistochemical staining
Briefly, dewaxed histological slides were stained 
using the indicated antibody at room temperature for 1 
h. The immunoactivity was detected using a Vectastain 
ABC kit (Vector Laboratories, Burlingame, CA, USA), 
and photographed by the microscope (Olympus, Melville, 
NY, USA)
Immunofluorescence
After blocking with 3% bovine serum albumin 
(BSA), cells on the coverslip were stained with phalloidin 
568 (Invitrogen) to detect F-actin at room temperature for 
1 h. Stained coverslips were mounted with 90% glycerol 
containing DAPI (Invitrogen), and photographed under the 
immunofluorescent microscope (Olympus).
Quantitative (Q)-Pcr
The cDNA (1 ng) was subjected to Q-PCR using 
SyBRGreen (Takara 
Bio, Shiga, Japan) by CFX96 REAL-TIME PCR 
DET SYS (Bio-Rad Laboratories, 
Hercules, CA, USA). The primers were listed in 
Supplementary Table S2.
In vitro transwell invasion assay
The experimental procedure was described 
previously [46].
Wound-healing assay
We performed the same procedure with the previous 
study [46].
Human specimens of lung cancer
The procedure of collecting human specimens 
conformed to the human ethics and was approved by the 
Clinical Research Ethics Committee at NCKU Medical 
Center.
statistical analysis
Student’s t test was used to compare the difference 
between two groups. Two-way analysis of variance 
(ANOVA) was used to compare the increasing cytotoxic 
effect of BA and SYK023 on H1299 cells. Kaplan–Meier 
method was used to calculate survival curves and survival 
rate was compared according to log-rank test.
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